As of February 19, 2026 a clinical trial is advancing to study the neurophysiological effects of tapering medications in patients treated with spinal cord stimulation using an evoke closed loop system for Persistent Spinal Pain Syndrome Type 2 in the lower spine. The sponsor Brai²n is recruiting participants. Clinicians and device developers should watch this study for potential implications on practice safety and device performance.
What is PSPS T2 and how does spinal cord stimulation work?
Persistent Spinal Pain Syndrome Type 2 describes chronic spine related pain conditions involving the lower spine. It can limit function and quality of life. Spinal cord stimulation is a therapy intended to modulate pain signaling by delivering electrical stimulation to the spinal cord. The current study notes the use of an Evoke closed loop system that adjusts stimulation based on neurophysiological signals. The aim is to understand how tapering medications interacts with device function and patient response, with a focus on safety and effectiveness.
What has changed in this trial design and what is the intervention?
The trial centers on neurophysiological sensitivity to spinal cord stimulation in PSPS T2. The intervention is Spinal Cord Stimulation with Evoke closed loop system. This approach relies on real time feedback to adjust output and may influence how tapering medications affect therapy. The sponsor Brai²n is recruiting for this study.
What is an Evoke closed loop system?
The Evoke system is described as a closed loop device that uses neurophysiological signals to guide stimulation. This device oriented design aims to personalize therapy and maintain safety in real world use. Details beyond the current report are not provided here.
What does this mean for safety and regulatory oversight?
The description of the trial underlines the need for clear statements on intended use and performance of the device in a context that includes medication taper. Regulators and health care providers expect thorough documentation of device behavior under changing pharmacology. The ongoing recruitment suggests that data will inform future clinical practice and regulatory communications around Evoke closed loop spinal cord stimulation in PSPS T2.
FAQ
- What condition is PSPS T2 addressing and who is affected?
- What is the intervention used in the study?
- Who sponsors the trial and where is it recruiting?
- Where can I find more information?
Conclusion This study aims to clarify how medication tapering interacts with neurophysiological responses during Spinal Cord Stimulation with an Evoke closed loop system. Findings may influence clinical practice and device safety considerations in PSPS T2 care.
Disclaimer This article is for professional readers and is not legal advice.
https://clinicaltrials.gov/study/NCT07413731?term=medical+device